Veracyte (VCYT) Stock Forecast, Price Target & Predictions
VCYT Stock Forecast
Veracyte stock forecast is as follows: an average price target of $26.00 (represents a -24.22% downside from VCYT’s last price of $34.31) and a rating consensus of 'Buy', based on 5 wall street analysts offering a 1-year stock forecast.
VCYT Price Target
The average price target for Veracyte (VCYT) is $26.00 based on 1-year price targets from 5 Wall Street analysts in the past 3 months, with a price target range of $26.00 to $26.00. This represents a potential -24.22% downside from VCYT's last price of $34.31.
VCYT Analyst Ratings
According to 5 Wall Street analysts, Veracyte's rating consensus is 'Buy'. The analyst rating breakdown for VCYT stock is 0 'Strong Buy' (0.00%), 4 'Buy' (80.00%), 0 'Hold' (0.00%), 1 'Sell' (20.00%), and 0 'Strong Sell' (0.00%).
Veracyte Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Aug 12, 2024 | Tejas Savant | Morgan Stanley | $26.00 | $29.41 | -11.58% | -24.22% |
| May 04, 2022 | - | Morgan Stanley | $23.00 | $21.00 | 9.55% | -32.96% |
| May 04, 2022 | - | Needham | $26.00 | $21.46 | 21.16% | -24.22% |
The latest Veracyte stock forecast, released on Aug 12, 2024 by Tejas Savant from Morgan Stanley, set a price target of $26.00, which represents a -11.58% decrease from the stock price at the time of the forecast ($29.41), and a -24.22% decrease from VCYT last price ($34.31).
Veracyte Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | 1 | 1 |
| Avg Price Target | - | $26.00 | $26.00 |
| Last Closing Price | $34.31 | $34.31 | $34.31 |
| Upside/Downside | -100.00% | -24.22% | -24.22% |
In the current month, the average price target of Veracyte stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Veracyte's last price of $34.31. This month's average price target is down -100.00% compared to last quarter, and down -100.00% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Oct 15, 2024 | UBS | - | Buy | Initialise |
| Oct 10, 2024 | Guggenheim | - | Buy | Initialise |
| Aug 12, 2024 | Morgan Stanley | Underweight | Underweight | Hold |
| Aug 07, 2024 | Needham | Buy | Buy | Hold |
| Aug 07, 2024 | William Blair | Outperform | Outperform | Hold |
| Jan 05, 2023 | Scotiabank | - | Sector Outperform | Initialise |
Veracyte's last stock rating was published by UBS on Oct 15, 2024. The company Initialise its VCYT rating from "null" to "Buy".
Veracyte Financial Forecast
Veracyte Revenue Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | $98.20M | $90.11M | $90.32M | $82.42M | $80.30M | $75.59M | $72.86M | $67.78M | $67.34M | $60.37M | $55.10M | $36.70M | $34.54M | $31.12M | $20.70M | $31.12M | $29.73M | $30.97M |
| Avg Forecast | $138.80M | $132.77M | $134.71M | $118.51M | $126.86M | $121.01M | $122.70M | $110.10M | $115.03M | $109.90M | $100.27M | $93.35M | $91.97M | $84.36M | $83.05M | $75.80M | $73.94M | $66.41M | $68.08M | $61.92M | $62.52M | $54.00M | $48.07M | $32.67M | $32.20M | $23.88M | $17.08M | $30.61M | $29.57M | $30.06M |
| High Forecast | $138.80M | $132.77M | $134.71M | $118.51M | $126.86M | $121.01M | $122.70M | $110.10M | $115.03M | $110.75M | $100.27M | $93.35M | $91.97M | $85.67M | $83.05M | $75.80M | $73.94M | $66.41M | $68.08M | $61.92M | $62.52M | $54.00M | $48.07M | $32.67M | $32.20M | $23.88M | $17.08M | $30.61M | $29.57M | $30.06M |
| Low Forecast | $138.80M | $132.77M | $134.71M | $118.51M | $126.86M | $121.01M | $122.70M | $110.10M | $115.03M | $108.89M | $100.27M | $93.35M | $91.97M | $83.08M | $83.05M | $75.80M | $73.94M | $66.41M | $68.08M | $61.92M | $62.52M | $54.00M | $48.07M | $32.67M | $32.20M | $23.88M | $17.08M | $30.61M | $29.57M | $30.06M |
| # Analysts | 3 | 3 | 3 | 3 | 4 | 4 | 4 | 4 | 3 | 6 | 3 | 1 | 1 | 8 | 5 | 4 | 4 | 3 | 4 | 3 | 5 | 4 | 5 | 4 | 5 | 8 | 7 | 6 | 5 | 5 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | 1.07% | 1.07% | 1.09% | 1.09% | 1.09% | 1.14% | 1.07% | 1.09% | 1.08% | 1.12% | 1.15% | 1.12% | 1.07% | 1.30% | 1.21% | 1.02% | 1.01% | 1.03% |
Veracyte's average Quarter revenue forecast for Mar 24 based on 1 analysts is $93.35M, with a low forecast of $93.35M, and a high forecast of $93.35M. VCYT's average Quarter revenue forecast represents a -4.93% decrease compared to the company's last Quarter revenue of $98.20M (Dec 23).
Veracyte EBITDA Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 3 | 3 | 3 | 3 | 4 | 4 | 4 | 4 | 3 | 6 | 3 | 1 | 1 | 8 | 5 | 4 | 4 | 3 | 4 | 3 | 5 | 4 | 5 | 4 | 5 | 8 | 7 | 6 | 5 | 5 |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | $5.03M | - | $-1.19M | $-3.83M | $1.14M | $-3.36M | $-5.34M | $-7.75M | $-4.91M | $-9.28M | $-4.63M | $-43.06M | $2.11M | $-2.08M | $-9.00M | $-9.69M | $-6.10M | $295.00K |
| Avg Forecast | $-16.25M | $-15.55M | $-15.77M | $-13.88M | $-14.85M | $-14.17M | $-14.37M | $-12.89M | $-13.47M | $-12.87M | $-11.74M | $-20.42M | $-10.77M | $-9.88M | $-9.73M | $-18.56M | $-8.66M | $-7.78M | $-7.97M | $-16.87M | $-7.32M | $-6.32M | $-5.63M | $-135.64M | $-3.77M | $-2.80M | $-2.00M | $-7.75M | $-3.46M | $-3.52M |
| High Forecast | $-16.25M | $-15.55M | $-15.77M | $-13.88M | $-14.85M | $-14.17M | $-14.37M | $-12.89M | $-13.47M | $-12.75M | $-11.74M | $-16.33M | $-10.77M | $-9.73M | $-9.73M | $-14.85M | $-8.66M | $-7.78M | $-7.97M | $-13.50M | $-7.32M | $-6.32M | $-5.63M | $-108.51M | $-3.77M | $-2.80M | $-2.00M | $-6.20M | $-3.46M | $-3.52M |
| Low Forecast | $-16.25M | $-15.55M | $-15.77M | $-13.88M | $-14.85M | $-14.17M | $-14.37M | $-12.89M | $-13.47M | $-12.97M | $-11.74M | $-24.50M | $-10.77M | $-10.03M | $-9.73M | $-22.27M | $-8.66M | $-7.78M | $-7.97M | $-20.25M | $-7.32M | $-6.32M | $-5.63M | $-162.77M | $-3.77M | $-2.80M | $-2.00M | $-9.30M | $-3.46M | $-3.52M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | -0.47% | - | 0.12% | 0.21% | -0.13% | 0.43% | 0.67% | 0.46% | 0.67% | 1.47% | 0.82% | 0.32% | -0.56% | 0.74% | 4.50% | 1.25% | 1.76% | -0.08% |
1 analysts predict VCYT's average Quarter EBITDA for Mar 24 to be $-20.42M, with a high of $-16.33M and a low of $-24.50M. This is -506.01% lower than Veracyte's previous annual EBITDA (Dec 23) of $5.03M.
Veracyte Net Income Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 3 | 3 | 3 | 3 | 4 | 4 | 4 | 4 | 3 | 6 | 3 | 1 | 1 | 8 | 5 | 4 | 4 | 3 | 4 | 3 | 5 | 4 | 5 | 4 | 5 | 8 | 7 | 6 | 5 | 5 |
| Net Income | - | - | - | - | - | - | - | - | - | - | - | - | $-28.29M | $-29.62M | $-8.40M | $-5.68M | $-3.84M | $-8.72M | $-9.53M | $-14.46M | $-10.53M | $-14.13M | $-9.04M | $-41.87M | $26.86K | $-4.12M | $-11.03M | $-11.72M | $-7.46M | $-730.00K |
| Avg Forecast | $22.06M | $19.17M | $20.43M | $14.39M | $11.90M | $8.37M | $10.49M | $5.15M | $5.39M | $2.49M | $-1.27M | $-20.41M | $-7.74M | $-11.30M | $-11.76M | $-18.56M | $-11.66M | $-19.93M | $-17.20M | $-16.87M | $-12.39M | $-13.12M | $-19.41M | $-131.88M | $-7.46M | $-16.20M | $-20.53M | $-9.37M | $-6.30M | $-5.66M |
| High Forecast | $22.06M | $19.17M | $20.43M | $14.39M | $11.90M | $8.37M | $10.49M | $5.15M | $5.39M | $7.48M | $-1.27M | $-16.33M | $2.21M | $-9.04M | $-11.76M | $-14.85M | $-11.66M | $-19.93M | $-17.20M | $-13.50M | $-12.39M | $-13.12M | $-19.41M | $-105.51M | $-7.46M | $-16.20M | $-20.53M | $-7.50M | $-6.30M | $-5.66M |
| Low Forecast | $22.06M | $19.17M | $20.43M | $14.39M | $11.90M | $8.37M | $10.49M | $5.15M | $5.39M | $-7.48M | $-1.27M | $-24.50M | $-14.38M | $-12.81M | $-11.76M | $-22.27M | $-11.66M | $-19.93M | $-17.20M | $-20.25M | $-12.39M | $-13.12M | $-19.41M | $-158.26M | $-7.46M | $-16.20M | $-20.53M | $-11.25M | $-6.30M | $-5.66M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | 3.65% | 2.62% | 0.71% | 0.31% | 0.33% | 0.44% | 0.55% | 0.86% | 0.85% | 1.08% | 0.47% | 0.32% | -0.00% | 0.25% | 0.54% | 1.25% | 1.18% | 0.13% |
Veracyte's average Quarter net income forecast for Mar 21 is $-131.88M, with a range of $-158.26M to $-105.51M. VCYT's average Quarter net income forecast represents a -491014.57% decrease compared to the company's last Quarter net income of $26.86K (Dec 20).
Veracyte SG&A Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 3 | 3 | 3 | 3 | 4 | 4 | 4 | 4 | 3 | 6 | 3 | 1 | 1 | 8 | 5 | 4 | 4 | 3 | 4 | 3 | 5 | 4 | 5 | 4 | 5 | 8 | 7 | 6 | 5 | 5 |
| SG&A | - | - | - | - | - | - | - | - | - | - | - | - | $46.89M | $40.68M | $50.80M | $48.59M | $42.34M | $43.28M | $43.80M | $44.15M | $41.06M | $47.46M | $34.71M | $62.17M | $33.84M | $19.11M | $21.14M | $25.03M | $22.40M | $19.35M |
| Avg Forecast | $93.10M | $89.05M | $90.36M | $79.49M | $85.09M | $81.17M | $82.30M | $73.85M | $77.15M | $73.71M | $67.25M | $63.05M | $61.69M | $56.58M | $55.71M | $57.32M | $49.60M | $44.54M | $45.66M | $52.11M | $41.93M | $36.22M | $32.24M | $21.91M | $21.60M | $16.02M | $11.45M | $20.02M | $19.83M | $20.16M |
| High Forecast | $93.10M | $89.05M | $90.36M | $79.49M | $85.09M | $81.17M | $82.30M | $73.85M | $77.15M | $74.28M | $67.25M | $75.66M | $61.69M | $57.46M | $55.71M | $68.79M | $49.60M | $44.54M | $45.66M | $62.53M | $41.93M | $36.22M | $32.24M | $21.91M | $21.60M | $16.02M | $11.45M | $24.03M | $19.83M | $20.16M |
| Low Forecast | $93.10M | $89.05M | $90.36M | $79.49M | $85.09M | $81.17M | $82.30M | $73.85M | $77.15M | $73.03M | $67.25M | $50.44M | $61.69M | $55.72M | $55.71M | $45.86M | $49.60M | $44.54M | $45.66M | $41.69M | $41.93M | $36.22M | $32.24M | $21.91M | $21.60M | $16.02M | $11.45M | $16.02M | $19.83M | $20.16M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | 0.76% | 0.72% | 0.91% | 0.85% | 0.85% | 0.97% | 0.96% | 0.85% | 0.98% | 1.31% | 1.08% | 2.84% | 1.57% | 1.19% | 1.85% | 1.25% | 1.13% | 0.96% |
Veracyte's average Quarter SG&A projection for Mar 24 is $63.05M, based on 1 Wall Street analysts, with a range of $50.44M to $75.66M. The forecast indicates a 34.46% rise compared to VCYT last annual SG&A of $46.89M (Dec 23).
Veracyte EPS Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 3 | 3 | 3 | 3 | 4 | 4 | 4 | 4 | 3 | 6 | 3 | 1 | 1 | 8 | 5 | 4 | 4 | 3 | 4 | 3 | 5 | 4 | 5 | 4 | 5 | 8 | 7 | 6 | 5 | 5 |
| EPS | - | - | - | - | - | - | - | - | - | - | - | - | $-0.39 | $-0.41 | $-0.12 | $-0.08 | $-0.05 | $-0.12 | $-0.13 | $-0.20 | $-0.15 | $-0.20 | $-0.13 | $-0.66 | - | $-0.08 | $-0.22 | $-0.24 | $-0.15 | $-0.02 |
| Avg Forecast | $0.29 | $0.25 | $0.26 | $0.19 | $0.15 | $0.11 | $0.14 | $0.07 | $0.07 | $0.03 | $-0.02 | $-0.16 | $-0.10 | $-0.15 | $-0.15 | $-0.13 | $-0.15 | $-0.26 | $-0.22 | $-0.23 | $-0.16 | $-0.17 | $-0.25 | $-0.12 | $-0.10 | $-0.21 | $-0.27 | $-0.20 | $-0.08 | $-0.07 |
| High Forecast | $0.29 | $0.25 | $0.26 | $0.19 | $0.15 | $0.11 | $0.14 | $0.07 | $0.07 | $0.10 | $-0.02 | $-0.16 | $0.03 | $-0.12 | $-0.15 | $-0.13 | $-0.15 | $-0.26 | $-0.22 | $-0.23 | $-0.16 | $-0.17 | $-0.25 | $-0.12 | $-0.10 | $-0.21 | $-0.27 | $-0.20 | $-0.08 | $-0.07 |
| Low Forecast | $0.29 | $0.25 | $0.26 | $0.19 | $0.15 | $0.11 | $0.14 | $0.07 | $0.07 | $-0.10 | $-0.02 | $-0.16 | $-0.19 | $-0.17 | $-0.15 | $-0.13 | $-0.15 | $-0.26 | $-0.22 | $-0.23 | $-0.16 | $-0.17 | $-0.25 | $-0.12 | $-0.10 | $-0.21 | $-0.27 | $-0.20 | $-0.08 | $-0.07 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | 3.89% | 2.80% | 0.79% | 0.59% | 0.35% | 0.46% | 0.58% | 0.86% | 0.93% | 1.18% | 0.52% | 5.50% | -0.00% | 0.38% | 0.83% | 1.22% | 1.84% | 0.20% |
According to 4 Wall Street analysts, Veracyte's projected average Quarter EPS for Mar 21 is $-0.12, with a low estimate of $-0.12 and a high estimate of $-0.12. This represents a -26017.92% decrease compared to VCYT previous annual EPS of - (Dec 20).
Veracyte Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| VTYX | Ventyx Biosciences | $2.45 | $33.86 | 1282.04% | Buy |
| QURE | uniQure | $6.28 | $53.67 | 754.62% | Buy |
| ENTA | Enanta Pharmaceuticals | $12.28 | $65.67 | 434.77% | Buy |
| FIXX | Q32 Bio | $0.93 | $2.70 | 190.32% | Buy |
| SLDB | Solid Biosciences | $6.32 | $17.50 | 176.90% | Buy |
| RCKT | Rocket Pharmaceuticals | $18.43 | $45.00 | 144.17% | Buy |
| GPCR | Structure Therapeutics | $39.62 | $92.40 | 133.22% | Buy |
| REPL | Replimune Group | $11.31 | $24.20 | 113.97% | Buy |
| SNDX | Syndax Pharmaceuticals | $19.89 | $36.00 | 81.00% | Buy |
| KROS | Keros Therapeutics | $61.09 | $102.00 | 66.97% | Buy |
| IDYA | IDEAYA Biosciences | $30.69 | $48.20 | 57.05% | Buy |
| VRDN | Viridian Therapeutics | $24.26 | $37.83 | 55.94% | Buy |
| CYTK | Cytokinetics | $54.53 | $83.23 | 52.63% | Buy |
| MGTX | MeiraGTx | $5.94 | $9.00 | 51.52% | Buy |
| MRUS | Merus | $51.74 | $77.86 | 50.48% | Buy |
| KURA | Kura Oncology | $18.09 | $25.67 | 41.90% | Buy |
| ANAB | AnaptysBio | $35.18 | $44.80 | 27.35% | Buy |
| CRNX | Crinetics Pharmaceuticals | $58.92 | $70.14 | 19.04% | Buy |
| PTGX | Protagonist Therapeutics | $47.02 | $50.00 | 6.34% | Buy |
| RYTM | Rhythm Pharmaceuticals | $51.03 | $48.60 | -4.76% | Buy |
| VCYT | Veracyte | $34.31 | $26.00 | -24.22% | Buy |
| CERE | Cerevel Therapeutics | $44.96 | $33.50 | -25.49% | Buy |
VCYT Forecast FAQ
Is Veracyte a good buy?
Yes, according to 5 Wall Street analysts, Veracyte (VCYT) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 4 'Buy' recommendations, accounting for 80.00% of VCYT's total ratings.
What is VCYT's price target?
Veracyte (VCYT) average price target is $26 with a range of $26 to $26, implying a -24.22% from its last price of $34.31. The data is based on 5 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will Veracyte stock go up soon?
According to Wall Street analysts' prediction for VCYT stock, the company can go down by -24.22% (from the last price of $34.31 to the average price target of $26), down by -24.22% based on the highest stock price target, and down by -24.22% based on the lowest stock price target.
Can Veracyte stock reach $50?
VCYT's average twelve months analyst stock price target of $26 does not support the claim that Veracyte can reach $50 in the near future.
What are Veracyte's analysts' financial forecasts?
Veracyte's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $480.67M (high $480.67M, low $480.67M), average EBITDA is $-56.284M (high $-56.284M, low $-56.284M), average net income is $35.92M (high $35.92M, low $35.92M), average SG&A $322.4M (high $322.4M, low $322.4M), and average EPS is $0.465 (high $0.465, low $0.465). VCYT's analysts financial forecasts for the fiscal year (Dec 2026) are as follows: average revenue is $524.8M (high $524.8M, low $524.8M), average EBITDA is $-61.451M (high $-61.451M, low $-61.451M), average net income is $76.05M (high $76.05M, low $76.05M), average SG&A $351.99M (high $351.99M, low $351.99M), and average EPS is $0.986 (high $0.986, low $0.986).
Did the VCYT's actual financial results beat the analysts' financial forecasts?
Based on Veracyte's last annual report (Dec 2023), the company's revenue was $361.05M, beating the average analysts forecast of $335.18M by 7.72%. Apple's EBITDA was $12.92M, missing the average prediction of $-48.935M by -126.39%. The company's net income was $-74.404M, beating the average estimation of $-49.363M by 50.73%. Apple's SG&A was $184.78M, missing the average forecast of $231.29M by -20.11%. Lastly, the company's EPS was $-1.02, beating the average prediction of $-0.534 by 91.10%. In terms of the last quarterly report (Dec 2023), Veracyte's revenue was $98.2M, beating the average analysts' forecast of $91.97M by 6.77%. The company's EBITDA was $5.03M, missing the average prediction of $-10.769M by -146.70%. Veracyte's net income was $-28.293M, beating the average estimation of $-7.744M by 265.35%. The company's SG&A was $46.89M, missing the average forecast of $61.69M by -23.98%. Lastly, the company's EPS was $-0.39, beating the average prediction of $-0.1 by 288.60%